Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | QPCT | Q16769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21592288 | 0.85 | CYP11B1 (0.50) | CYP19A1CYP11B1CYP11B2KMT2AALDH1A1 | |
| SCHEMBL21591446 | 0.85 | CYP11B1 (0.55) | CYP19A1CYP11B1CYP11B2KMT2AALDH1A1 | |
| SCHEMBL21592272 | 0.83 | NPC1 (0.48) | CYP19A1CYP11B1CYP11B2KMT2AALDH1A1 | |
| SCHEMBL21592248 | 0.79 | CYP19A1 (0.46) | CYP19A1CYP11B1CYP11B2KMT2AALDH1A1 | |
| SCHEMBL21592273 | 0.79 | CYP11B1 (0.53) | CYP19A1CYP11B1CYP11B2KMT2A | |
| SCHEMBL21591430 | 0.78 | CYP11B1 (0.64) | CYP19A1CYP11B1CYP11B2KMT2AALDH1A1 | |
| SCHEMBL21592271 | 0.77 | CYP11B1 (0.48) | CYP19A1CYP11B1CYP11B2ALDH1A1GSK3B | |
| SCHEMBL21592266 | 0.77 | ALDH1A1 (0.41) | CYP19A1CYP11B1CYP11B2KMT2AALDH1A1 | |
| SCHEMBL21592280 | 0.75 | CYP11B1 (0.48) | CYP19A1CYP11B1CYP11B2KMT2AALDH1A1 | |
| SCHEMBL21591568 | 0.74 | CYP11B1 (0.53) | CYP19A1CYP11B1CYP11B2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2024-12-10 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| WO-2019238786-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | STING1, IRF3, CGAS | CYP19A1 589/4885CYP11B1 43/4885CYP11B2 50/4885 |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | CYP19A1 589/4885CYP11B1 43/4885CYP11B2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.